Lipid Metabolism Practice Questions

Q: Which of the following fatty acids is a precursor of arachidonic acid?

Linoleic acid. **Explanation:** **1. Why Linoleic Acid is correct:** Arachidonic acid (C20:4, ω-6) is a semi-essential fatty acid. It can be synthesized in the human body only if its precursor, **Linoleic acid (C18:2, ω-6)**, is available. The conversion occurs in the endoplasmic reticulum through a series of elongation and desaturation reactions: *Linoleic acid → γ-Linolenic acid → Dihomo-γ-linolenic acid → Arachidonic acid.* Since humans cannot introduce double bonds beyond carbon 9, Linoleic acid (an essential fatty acid) must be obtained from the diet to produce arachidonic acid. **2. Why the other options are incorrect:** * **Linolenic acid (α-Linolenic acid):** This is an **ω-3** fatty acid. It serves as the precursor for Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA), not arachidonic acid. * **Oleic acid:** This is a monounsaturated **ω-9** fatty acid (C18:1). While it can be synthesized endogenously, it cannot be converted into ω-6 fatty acids like arachidonic acid. * **Palmitic acid:** This is a 16-carbon **saturated** fatty acid. It is the first fatty acid produced by the Fatty Acid Synthase (FAS) complex and serves as a precursor for longer-chain saturated and monounsaturated fats, but not polyunsaturated fatty acids (PUFAs) like arachidonic acid. **High-Yield Clinical Pearls for NEET-PG:** * **Essential Fatty Acids (EFA):** Only Linoleic and α-Linolenic acid are truly essential. Arachidonic acid becomes essential only if Linoleic acid is deficient in the diet. * **Prostaglandin Synthesis:** Arachidonic acid is the primary substrate for the **Cyclooxygenase (COX)** and **Lipoxygenase (LOX)** pathways, leading to the production of Prostaglandins, Thromboxanes, and Leukotrienes (Group 2 eicosanoids). * **Vanishing EFA:** Deficiency of EFAs leads to **Phrynoderma** (follicular hyperkeratosis) and poor wound healing.

Q: Lipoprotein X is elevated in which of the following conditions?

Primary biliary cirrhosis. **Explanation:** **Lipoprotein X (LpX)** is an abnormal, pathological low-density lipoprotein (LDL) that appears in the plasma of patients with **cholestasis**. Unlike normal lipoproteins, LpX lacks Apolipoprotein B-100 and is primarily composed of unesterified cholesterol and phospholipids (lecithin). 1. **Why Primary Biliary Cirrhosis (PBC) is correct:** PBC is a chronic cholestatic liver disease characterized by the destruction of intrahepatic bile ducts. In cholestasis, there is a **regurgitation of biliary lipids** (specifically lecithin and cholesterol) into the bloodstream. These lipids aggregate with albumin and Apolipoprotein C to form LpX. Therefore, LpX is a highly specific marker for obstructive jaundice and PBC. 2. **Why the other options are incorrect:** * **Indian Childhood Cirrhosis (ICC):** This is primarily a copper-overload liver disease. While it leads to cirrhosis, it is not classically defined by the specific lipoprotein abnormalities seen in obstructive cholestasis. * **Hypercholesterolemia:** This refers to elevated levels of normal LDL or VLDL. LpX is an *abnormal* lipoprotein and is not a feature of familial or dietary hypercholesterolemia. * **Alcoholic Cirrhosis:** While it involves liver damage, it typically presents with elevated VLDL or HDL abnormalities rather than the specific formation of LpX, which requires significant biliary obstruction. **High-Yield Pearls for NEET-PG:** * **LCAT Deficiency:** Besides cholestasis, LpX is also found in patients with **Lecithin-Cholesterol Acyltransferase (LCAT) deficiency**. * **Diagnostic Significance:** LpX is the most specific biochemical marker for differentiating obstructive (post-hepatic) jaundice from parenchymal liver disease. * **Composition:** It is unique because it contains **Apo C and Albumin**, but lacks Apo B. * **Pseudohyponatremia:** High levels of LpX can cause a "falsely low" sodium reading on certain lab tests.

Q: What is the first hormone produced in cholesterol synthesis?

Lanosterol. **Explanation:** The synthesis of cholesterol is a complex, multi-step process occurring primarily in the liver. The correct answer is **Lanosterol**, which is the **first tetracyclic sterol** (the characteristic four-ring steroid nucleus) formed in the pathway. The pathway follows this high-yield sequence: 1. **Acetyl-CoA** → HMG-CoA 2. **HMG-CoA** is reduced to **Mevalonate** (Rate-limiting step via *HMG-CoA Reductase*) 3. Mevalonate → Isoprenoid units (IPPs) → **Squalene** (a linear 30-carbon hydrocarbon) 4. Squalene undergoes cyclization to form **Lanosterol**. 5. Lanosterol then undergoes a series of approximately 19 steps to finally become **Cholesterol**. **Analysis of Incorrect Options:** * **A. Epinephrine:** This is a catecholamine hormone derived from the amino acid **Tyrosine**, not cholesterol. * **B. Ergosterol:** This is a sterol found in **fungal cell membranes**. While structurally similar to cholesterol, it is not an intermediate in human cholesterol synthesis. * **D. Secretin:** This is a peptide hormone produced by the S-cells of the duodenum; it is not derived from the lipid synthesis pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-Limiting Enzyme:** HMG-CoA Reductase (Target of **Statins**). * **Location:** Synthesis occurs in the **Cytosol** and **Endoplasmic Reticulum**. * **Key Intermediate:** Squalene is the last linear precursor before cyclization. * **Requirement:** Synthesis requires **NADPH** (primarily from the HMP Shunt) and **ATP**.

Q: The only energy-requiring step in fatty acid oxidation is catalyzed by which enzyme?

Thiokinase. ### Explanation The correct answer is **Thiokinase** (also known as **Acyl-CoA Synthetase**). **1. Why Thiokinase is Correct:** Fatty acid oxidation (Beta-oxidation) occurs in the mitochondria, but fatty acids must first be "activated" in the cytosol to enter the metabolic pathway. Thiokinase catalyzes the conversion of a free fatty acid into an **Acyl-CoA**. This is the **only energy-requiring step** in the entire process. It consumes **two high-energy phosphate bonds** because ATP is hydrolyzed to AMP and inorganic pyrophosphate (PPi). The subsequent hydrolysis of PPi by pyrophosphatase makes this reaction irreversible and drives the process forward. **2. Why the Other Options are Incorrect:** * **Acyl-CoA Dehydrogenase (Option B):** This is the first enzyme of the beta-oxidation cycle itself. It involves the oxidation of Acyl-CoA to trans-enoyl-CoA, which **generates energy** in the form of FADH₂ rather than consuming it. * **Thiolase (Option C):** This is the final enzyme of the beta-oxidation cycle. It performs a thiolytic cleavage to release Acetyl-CoA. It does not require ATP. * **Beta-hydroxy Acyl-CoA Dehydrogenase (Option D):** This is the third enzyme of the cycle. It oxidizes the hydroxyl group to a keto group, **generating energy** in the form of NADH. **3. NEET-PG High-Yield Pearls:** * **Location:** Activation (Thiokinase) occurs in the **outer mitochondrial membrane/cytosol**, while the actual oxidation occurs in the **mitochondrial matrix**. * **The Carnitine Shuttle:** While Thiokinase activates the fatty acid, the **Carnitine palmitoyltransferase (CPT) system** is the rate-limiting step for transporting long-chain fatty acids into the mitochondria. * **Net ATP Calculation:** When calculating the net ATP yield of palmitic acid (106 ATP), we subtract **2 ATP** specifically because of the Thiokinase step (ATP → AMP).

Q: In a child with cerebrohepatorenal syndrome presenting with hypotonia and hepatomegaly, the probable biochemical defect involves the accumulation of which substance?

Very long chain fatty acids. **Explanation:** **1. Why "Very long chain fatty acids" (VLCFAs) is correct:** The clinical presentation described—hypotonia, hepatomegaly, and "cerebrohepatorenal syndrome"—is the classic triad of **Zellweger Syndrome**. This is an autosomal recessive peroxisomal biogenesis disorder caused by mutations in *PEX* genes. Peroxisomes are essential for the **$\beta$-oxidation of Very Long Chain Fatty Acids (VLCFAs)** (fatty acids with $\ge$ 22 carbons). When peroxisomes are absent or dysfunctional, VLCFAs cannot be broken down and instead accumulate in the blood and tissues, particularly the brain and liver, leading to demyelination and organ dysfunction. **2. Why the other options are incorrect:** * **Pyruvate:** Accumulation is typically seen in Pyruvate Dehydrogenase deficiency or B1 deficiency, leading to lactic acidosis, not peroxisomal disorders. * **Short chain fatty acids:** These are metabolized in the mitochondria. Peroxisomes are specifically required for the initial breakdown of very long chains; once shortened, they are transferred to mitochondria. * **Acetyl CoA:** This is a product of fatty acid oxidation, not a substance that accumulates due to a lack of peroxisomes. In fact, impaired $\beta$-oxidation would lead to *decreased* production of Acetyl CoA. **High-Yield NEET-PG Clinical Pearls:** * **Zellweger Syndrome:** Often called "Empty Peroxisome" syndrome. Look for craniofacial dysmorphism (high forehead, wide fontanelles) and stippled epiphyses (chondrodysplasia punctata) on X-ray. * **Refsum Disease:** Another peroxisomal disorder, but due to a defect in **$\alpha$-oxidation**, leading to the accumulation of **Phytanic acid**. * **Adrenoleukodystrophy (ALD):** X-linked defect in the transport of VLCFAs into peroxisomes (ABCD1 mutation), leading to adrenal insufficiency and white matter loss.

Q: Which of the following is a cardioprotective fatty acid?

Oleic acid. **Explanation:** **Correct Answer: C. Oleic acid** **1. Why Oleic acid is correct:** Oleic acid (18:1; ω-9) is a **Monounsaturated Fatty Acid (MUFA)** and is the primary component of olive oil. It is considered cardioprotective because it effectively lowers **LDL-cholesterol** (the "bad" cholesterol) while maintaining or slightly increasing **HDL-cholesterol** (the "good" cholesterol). By improving the lipid profile and reducing oxidative stress on vascular endothelium, it decreases the risk of atherosclerosis and coronary heart disease (CHD). **2. Why other options are incorrect:** * **A & B (Palmitic and Stearic acid):** These are **Saturated Fatty Acids (SFA)**. Palmitic acid (16:0) is highly atherogenic as it significantly raises plasma LDL levels. While Stearic acid (18:0) is considered "neutral" because it is rapidly converted to oleic acid in the body, it is not classified as actively cardioprotective compared to MUFAs. * **D (Omega-3 fatty acids):** While Omega-3s (like EPA and DHA) are indeed cardioprotective, in the context of standard medical examinations, **Oleic acid** is the classic answer when discussing the benefits of the "Mediterranean Diet." *Note: If this were a multiple-select question, Omega-3 would be correct, but Oleic acid is the high-yield MUFA representative for this specific topic.* **3. High-Yield Clinical Pearls for NEET-PG:** * **P:S Ratio:** A high Polyunsaturated to Saturated fatty acid ratio in the diet is associated with lower cardiovascular risk. * **Trans-fatty acids:** These are the most harmful; they raise LDL and lower HDL. * **Mediterranean Diet:** Rich in Oleic acid (Olive oil), it is the gold standard for nutritional cardioprotection. * **Essential Fatty Acids:** Linoleic (ω-6) and Linolenic (ω-3) acids cannot be synthesized by humans due to the lack of desaturases beyond carbon 9.

Q: The small intestine secretes various triglyceride-rich lipoproteins, but the liver secretes only which type?

VLDL (Very Low-Density Lipoprotein). ### Explanation The liver and the small intestine are the two primary sites for the synthesis of triglyceride-rich lipoproteins. However, they utilize different apolipoproteins and pathways based on the source of the lipids. **1. Why VLDL is the Correct Answer:** The liver synthesizes **VLDL (Very Low-Density Lipoprotein)** to transport endogenous triglycerides (synthesized in the liver from excess carbohydrates or free fatty acids) to peripheral tissues. The structural hallmark of VLDL is **Apo B-100**. While the liver can produce HDL precursors, VLDL is the specific triglyceride-rich lipoprotein it secretes into the circulation. **2. Analysis of Incorrect Options:** * **A. Chylomicrons:** These are synthesized exclusively by the **enterocytes of the small intestine** to transport exogenous (dietary) lipids. They contain **Apo B-48**, a truncated version of Apo B-100 produced via RNA editing. * **C. LDL:** LDL is not secreted directly by any organ. It is a "metabolic end-product" formed in the plasma from VLDL via the action of Lipoprotein Lipase (LPL) and Cholesterol Ester Transfer Protein (CETP). * **D. HDL:** While the liver and intestine both secrete nascent HDL (Apo A-1), HDL is a **cholesterol-rich** lipoprotein, not a triglyceride-rich one. Its primary role is reverse cholesterol transport. **3. NEET-PG High-Yield Facts:** * **Apo B-48 vs. Apo B-100:** Both are products of the same gene. In the intestine, the enzyme **cytidine deaminase** creates a stop codon, resulting in the shorter Apo B-48 (48% of the protein). * **Abetalipoproteinemia:** A deficiency of Microsomal Triglyceride Transfer Protein (MTP) leads to an inability to load lipids onto Apo B, resulting in the absence of both Chylomicrons and VLDL. * **Rate-limiting step:** The assembly of VLDL in the liver requires MTP and Apo B-100.

Q: What is the end product of even-chain fatty acid oxidation?

Acetyl Co-A. **Explanation:** The oxidation of fatty acids primarily occurs via the **$\beta$-oxidation pathway** within the mitochondria. **1. Why Acetyl-CoA is correct:** In the $\beta$-oxidation of **even-chain fatty acids** (e.g., Palmitic acid), the fatty acid chain undergoes a repetitive four-step cycle (oxidation, hydration, oxidation, and thiolysis). In each cycle, two carbon atoms are cleaved from the carboxyl end of the fatty acyl-CoA molecule. The final cleavage of a four-carbon intermediate (Acetoacetyl-CoA) yields **two molecules of Acetyl-CoA**. Therefore, the entire even-chain fatty acid is completely degraded into Acetyl-CoA units, which then enter the TCA cycle for ATP production. **2. Why other options are incorrect:** * **Propionyl-CoA:** This is the end product of **odd-chain fatty acid** oxidation. In the final round of $\beta$-oxidation for odd-chain fats, a five-carbon fragment is cleaved into one Acetyl-CoA and one three-carbon Propionyl-CoA. * **Malonyl-CoA:** This is an intermediate of **fatty acid synthesis** (lipogenesis), not oxidation. It acts as a potent inhibitor of Carnitine Palmitoyltransferase-I (CPT-I), preventing a futile cycle by stopping fatty acid breakdown while synthesis is active. **Clinical Pearls for NEET-PG:** * **Site:** $\beta$-oxidation occurs in the mitochondrial matrix; Fatty acid synthesis occurs in the cytosol. * **Rate-limiting step:** The transport of fatty acids into the mitochondria via the **Carnitine Shuttle** (inhibited by Malonyl-CoA). * **Energy Yield:** Oxidation of one molecule of Palmitate (16C) yields a net of **106 ATP**. * **Odd-chain metabolism:** Propionyl-CoA is converted to Succinyl-CoA (a TCA cycle intermediate) via a Vitamin B12-dependent pathway. This makes odd-chain fatty acids **glucogenic**.

Q: Which of the following is not a ketone body?

Acetic acid. **Explanation:** Ketone bodies are water-soluble molecules produced by the liver from fatty acids during periods of low food intake (fasting), carbohydrate restrictive diets, or untreated type 1 diabetes. The process, known as **ketogenesis**, occurs in the mitochondrial matrix of hepatocytes. **Why Acetic Acid is the Correct Answer:** Acetic acid (Option B) is a two-carbon carboxylic acid. While it is related to the metabolism of Acetyl-CoA, it is **not** classified as a ketone body. In the context of metabolism, acetic acid is usually found in its activated form, Acetyl-CoA, which serves as the precursor for ketogenesis but is not a ketone body itself. **Analysis of Incorrect Options:** * **Acetoacetate (Option C):** This is the "primary" ketone body synthesized from Acetyl-CoA. It is a true keto-acid. * **Beta-hydroxybutyric acid (Option D):** Formed by the reduction of acetoacetate. Although technically a hydroxy-acid (lacking a keto group), it is clinically and biochemically classified as a ketone body. It is the most abundant ketone body in the blood during ketosis. * **Acetone (Option A):** Produced by the spontaneous non-enzymatic decarboxylation of acetoacetate. It is highly volatile and excreted via the lungs. **NEET-PG High-Yield Pearls:** 1. **Site of Synthesis:** Liver (mitochondria); however, the liver **cannot** utilize ketone bodies because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). 2. **Rate-limiting Enzyme:** HMG-CoA Synthase (Mitochondrial). 3. **Detection:** The **Rothera’s Test** detects Acetoacetate and Acetone, but it does **not** detect Beta-hydroxybutyrate. 4. **Clinical Sign:** The "fruity odor" of the breath in Diabetic Ketoacidosis (DKA) is due to the excretion of Acetone.

Question 1

Which of the following fatty acids is a precursor of arachidonic acid?

Accepted Answer

Linoleic acid

Answer

Linolenic acid

Answer

Oleic acid

Answer

Palmitic acid

Question 2

Lipoprotein X is elevated in which of the following conditions?

Accepted Answer

Primary biliary cirrhosis

Answer

Indian childhood cirrhosis

Answer

Hypercholesterolemia

Answer

Alcoholic cirrhosis

Question 3

What is the first hormone produced in cholesterol synthesis?

Accepted Answer

Lanosterol

Answer

Epinephrine

Answer

Ergosterol

Answer

Secretin

Question 4

Which of the following oils contains the maximum amount of essential fatty acids?

Accepted Answer

Sunflower oil

Answer

Coconut oil

Answer

Mustard oil

Answer

Groundnut oil

Question 5

The only energy-requiring step in fatty acid oxidation is catalyzed by which enzyme?

Accepted Answer

Thiokinase

Answer

Acyl co A dehydrogenase

Answer

Thiolase

Answer

Beta hydroxy Acyl co A dehydrogenase

Question 6

In a child with cerebrohepatorenal syndrome presenting with hypotonia and hepatomegaly, the probable biochemical defect involves the accumulation of which substance?

Accepted Answer

Very long chain fatty acids

Answer

Pyruvate

Answer

Short chain fatty acids

Answer

Acetyl CoA

Question 7

Which of the following is a cardioprotective fatty acid?

Accepted Answer

Oleic acid

Answer

Palmitic acid

Answer

Stearic acid

Answer

Omega-3 fatty acids

Question 8

The small intestine secretes various triglyceride-rich lipoproteins, but the liver secretes only which type?

Accepted Answer

VLDL (Very Low-Density Lipoprotein)

Answer

Chylomicrons

Answer

LDL (Low-Density Lipoprotein)

Answer

HDL (High-Density Lipoprotein)

Question 9

What is the end product of even-chain fatty acid oxidation?

Accepted Answer

Acetyl Co-A

Answer

Propionyl Co-A

Answer

Malonyl Co-A

Answer

None of the above

Question 10

Which of the following is not a ketone body?

Accepted Answer

Acetic acid

Answer

Acetone

Answer

Acetoacetate

Answer

Beta-hydroxybutyric acid

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?